Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial
- PMID: 22565936
- DOI: 10.1161/CIRCULATIONAHA.111.082313
Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial
Abstract
Background: The efficacy of cardiac pacing for prevention of syncopal recurrences in patients with neurally mediated syncope is controversial. We wanted to determine whether pacing therapy reduces syncopal recurrences in patients with severe asystolic neurally mediated syncope.
Methods and results: Double-blind, randomized placebo-controlled study conducted in 29 centers in the Third International Study on Syncope of Uncertain Etiology (ISSUE-3) trial. Patients were ≥40 years, had experienced ≥3 syncopal episodes in the previous 2 years. Initially, 511 patients, received an implantable loop recorder; 89 of these had documentation of syncope with ≥3 s asystole or ≥6 s asystole without syncope within 12 ± 10 months and met criteria for pacemaker implantation; 77 of 89 patients were randomly assigned to dual-chamber pacing with rate drop response or to sensing only. The data were analyzed on intention-to-treat principle. There was syncope recurrence during follow-up in 27 patients, 19 of whom had been assigned to pacemaker OFF and 8 to pacemaker ON. The 2-year estimated syncope recurrence rate was 57% (95% CI, 40-74) with pacemaker OFF and 25% (95% CI, 13-45) with pacemaker ON (log rank: P=0.039 at the threshold of statistical significance of 0.04). The risk of recurrence was reduced by 57% (95% CI, 4-81). Five patients had procedural complications: lead dislodgment in 4 requiring correction and subclavian vein thrombosis in 1 patient.
Conclusions: Dual-chamber permanent pacing is effective in reducing recurrence of syncope in patients ≥40 years with severe asystolic neurally mediated syncope. The observed 32% absolute and 57% relative reduction in syncope recurrence support this invasive treatment for the relatively benign neurally mediated syncope.
Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359203.
Comment in
-
Permanent pacemaker therapy for neurally mediated syncope.Circulation. 2012 May 29;125(21):2552-3. doi: 10.1161/CIRCULATIONAHA.112.109280. Epub 2012 May 7. Circulation. 2012. PMID: 22565938 No abstract available.
-
Highlights in clinical autonomic neurosciences: non-pharmacological therapy for vasovagal syncope.Auton Neurosci. 2013 Jan;173(1-2):3-5. doi: 10.1016/j.autneu.2012.09.001. Epub 2012 Sep 30. Auton Neurosci. 2013. PMID: 23031338 No abstract available.
Similar articles
-
Cardiac pacing in patients with neurally mediated syncope and documented asystole: effectiveness analysis from the Third International Study on Syncope of Uncertain Etiology (ISSUE-3) Registry.Europace. 2014 Apr;16(4):595-9. doi: 10.1093/europace/eut323. Epub 2014 Jan 9. Europace. 2014. PMID: 24406537 Clinical Trial.
-
Benefit of pacemaker therapy in patients with presumed neurally mediated syncope and documented asystole is greater when tilt test is negative: an analysis from the third International Study on Syncope of Uncertain Etiology (ISSUE-3).Circ Arrhythm Electrophysiol. 2014 Feb;7(1):10-6. doi: 10.1161/CIRCEP.113.001103. Epub 2013 Dec 12. Circ Arrhythm Electrophysiol. 2014. PMID: 24336948 Clinical Trial.
-
International study on syncope of uncertain aetiology 3 (ISSUE 3): pacemaker therapy for patients with asystolic neurally-mediated syncope: rationale and study design.Europace. 2007 Jan;9(1):25-30. doi: 10.1093/europace/eul135. Europace. 2007. PMID: 17224418 Clinical Trial.
-
Reflex vasovagal syncope--is there a benefit in pacemaker therapy?Rev Port Cardiol. 2014 May;33(5):297-303. doi: 10.1016/j.repc.2014.02.007. Epub 2014 Jun 2. Rev Port Cardiol. 2014. PMID: 24895017 Review. English, Portuguese.
-
Second Vasovagal Pacemaker Study (VPS II): rationale, design, results, and implications for practice and future clinical trials.Card Electrophysiol Rev. 2003 Dec;7(4):411-5. doi: 10.1023/B:CEPR.0000023157.37745.76. Card Electrophysiol Rev. 2003. PMID: 15071266 Review.
Cited by
-
JCS/JHRS 2022 Guideline on Diagnosis and Risk Assessment of Arrhythmia.J Arrhythm. 2024 Jun 12;40(4):655-752. doi: 10.1002/joa3.13052. eCollection 2024 Aug. J Arrhythm. 2024. PMID: 39139890 Free PMC article. No abstract available.
-
Therapeutic options for neurocardiogenic syncope: a meta-analysis of randomised trials with and without blinding.Open Heart. 2024 Jun 18;11(1):e002669. doi: 10.1136/openhrt-2024-002669. Open Heart. 2024. PMID: 38890128 Free PMC article.
-
Unconventional diagnosis of bradyarrhythmic syncope in Brugada syndrome: a case report.Eur Heart J Case Rep. 2024 Apr 22;8(5):ytae201. doi: 10.1093/ehjcr/ytae201. eCollection 2024 May. Eur Heart J Case Rep. 2024. PMID: 38711682 Free PMC article.
-
Cardioneuroablation for Cardioinhibitory Vasovagal Syncope: Rationale, Approaches, and Its Role in Long-Term Management.Curr Cardiovasc Risk Rep. 2024 Apr;18(4):55-64. doi: 10.1007/s12170-024-00736-7. Epub 2024 Apr 16. Curr Cardiovasc Risk Rep. 2024. PMID: 38707611
-
New Guidelines of Pediatric Cardiac Implantable Electronic Devices: What Is Changing in Clinical Practice?J Cardiovasc Dev Dis. 2024 Mar 27;11(4):99. doi: 10.3390/jcdd11040099. J Cardiovasc Dev Dis. 2024. PMID: 38667717 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
